Keywords: Daiichi Sankyo, Ranbaxy, Mid-trm business plan, US problems, Emerging markets,

Daiichi Sankyo plans to double profits in next three year, with focus on developing Ranbaxy unit

Article | 15 March 2010

Japanese drug major Daiichi Sankyo, which has 64% control of Ranbaxy, India’s largest pharmaceutical by global sales, revealed in its ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in